Sunday, February 22, 2009

Medicare-PartD.com Provides Seniors with a Preview of their 2010 Medicare Part D Prescription Drug Plan Costs

Medicare-PartD.com Provides Seniors with a Preview of their 2010 Medicare Part D Prescription Drug Plan Costs

Seniors can expect a smaller increase in 2010 Medicare Part D prescription drug plan parameters as compared to the increases they saw in 2009. Most Medicare Part D plan parameters, such as the initial deductible or out-of-pocket expense, will increase by only 3.13% in 2010, as compared to the 7.54% increase in the same values in 2009. To help the Medicare community better understand the 2010 changes, Medicare-PartD.com (http://www.medicare-partd.com/2010) has released the 2010 PDP-Planner, a simple to use online tool that illustrates how prescription drug costs change throughout the year and through the different phases of prescription drug coverage.

Saint Augustine, FL (Vocus) February 22, 2009 -- Seniors and Medicare beneficiaries can plan on increases in 2010 Medicare Part D prescription drug plan coverage parameters, but the changes are not so extreme as in previous years. Based on the recently released information from the Centers for Medicare and Medicaid Services (CMS), Medicare Part D plan parameters such as initial deductible, initial coverage limit and out-of-pocket threshold limits will increase in 2010 by 3.13% as compared to the 7.54% increase in 2009. An online summary comparing the CMS Medicare Part D defined standard benefit parameters from 2006 through 2010 are available at Medicare-PartD.com/2010 (http://www.medicare-partd.com/2010). Several of the 2010 low-income subsidy or extra-help values are still tentative and will be finalized as additional information becomes available.

To help seniors and other Medicare beneficiaries better understand the 2010 changes in the Part D plan benefit parameters, Medicare-PartD.com released their online 2010 PDP-Planner (http://www.medicare-partd.com/PartD-PartDCoverageGapCalculator10Xphp.php) tool. PDP-Planner allows users to visualize how they could potentially move through their Medicare Part D plan from initial deductible (if applicable) into the initial coverage phase, through the coverage gap, and maybe even into the catastrophic coverage portion of their Medicare Part D coverage.

"Unfortunately, even with three years of experience, we are finding that many people are still having difficulty understanding the coverage provided by their current Part D plans," noted Dr. Susan Johnson, technical director of the Medicare-PartD.com website. "It is our hope that the 2010 PDP-Planner will help Medicare Part D beneficiaries visualize prescription spending during the various phases of next year’s Part D plan coverage. To help people get started, we have provided a few PDP-Planner examples (http://www.medicare-partd.com/PartD-PartDCoverageGapCalculator10Xphp.php?pgtype=ex1) for those unfamiliar with the phases of a Medicare Part D prescription drug plan."

Users of PDP-Planner can enter estimated retail prescription costs based on their current drug spending and, if desired, change Medicare Part D plan parameters values, such as the initial deductible, to get an idea of how they will move through the phases of their Part D plan. For instance, a Medicare beneficiary who chooses a 2010 Part D plan modeled after the CMS defined standard plan will notice the slight increase in the initial deductible limits. The 2010 initial annual deductible will increase to $305 from the current 2009 value of $295. Beneficiaries will enter the 2010 donut hole or coverage gap when the total retail cost of their prescription drug purchases reaches the initial coverage limit of $2,780, an $80 increase over the 2009 Initial Coverage Limit of $2,700. In addition, people who enroll into a standard benefit plan with high prescription drug costs can begin to prepare for increases in total out of pocket expense (or TrOOP) that they must personally spend before exiting the donut hole and entering the catastrophic coverage portion of their prescription drug plan. The out of pocket threshold will increase to $4,500 in 2010 from the current 2009 value of $4,350.

"Our PDP-Planner is designed to provide an estimate based on the CMS defined standard benefit and, although most private Medicare Part D plans offer a variation of deductibles and cost-sharing options, we find that this defined standard benefit acts as a good benchmark for upcoming Part D coverage," added Dr. Johnson.

PDP-Planner is available at no cost and users have the option to have a copy of their PDP-Planner results sent directly to them via eMail. The 2009 PDP-Planner can be found at PDP-Planner.com/2010 (http://www.pdp-planner.com/2010) and joins the other online tools, resources, the free monthly Medicare Part D Newsletter (http://www.medicare-partd.com/PartD-StayingInformedOn-Medicare-PartD.php), and tutorials designed to help Medicare beneficiaries, advocates, advisors, and insurance agents navigate the Medicare prescription drug program.

About the Website Medicare-PartD.com

Medicare-PartD.com is one of the largest private internet resources for Medicare Part D prescription drug information. The Medicare-PartD.com website is designed and operated by Q1Group LLC (Saint Augustine, FL).

# # #



Contact Information Lynnea Christner

Q1Group LLC

http://www.medicare-partd.com/2010

904-461-8994

Susan Johnson MS-MIS, MBA, PhD

Q1Group LLC

http://www.medicare-partd.com/PartD-PartDCoverageGapCalculator10Xphp.php?pgtype=ex1

904-461-8994



Saturday, February 21, 2009

Separating Fact from Bioidentical Hype

Separating Fact from Bioidentical Hype

Hot from Menopausal Symptoms and Bothered by the Media Hype about Hormone Replacement? People are hearing about bioidentical hormone replacement along with more traditional types of prescribed hormone medication from the Oprah show and other media. Lets separate Fact from Fiction. The word "bioidentical" is not an accurate medical description of this new, unregulated substance and it certainly is not exactly like the hormones the body produces otherwise there would not be a measurable and clinically evident toxic build-up in the body. In "Revitalize Your Hormones: Dr. Dale's 7 Steps to a Happier, Healthier, and Sexier You" (Wiley; May 2005), Dr. Theresa Dale offers a medically proven natural alternative to invasive and dangerous hormone replacement therapies. Dale invented the world's only clinically proven, FDA registered, homeopathic hormone rejuvenation formulas used for restoring hormone balance without side effects.

(PRWEB) February 19, 2009 -- Hot from Menopausal Symptoms and Bothered by the Media Hype about Hormone Replacement? People are hearing about bioidentical hormone replacement along with more traditional types of prescribed hormone medication from the Oprah show and other media. Lets separate Fact from Fiction. The new buzz word "bioidentical" is deceptive. It's not an accurate medical description of this new, unregulated substance and it is not exactly like the body produces. Clearly there is a measurable and clinically evident toxic build-up in the body.

Bioidentical hormone replacement is not natural even though it originates from yam or soy; it has been compounded and thus a synthetic. That's right; health providers perform thousands of before and after saliva tests on patients and it is clear that there is a toxic build up of all hormone replacement including bioidentical HRT.

Women are wary of recent warnings linking hormone replacement therapy with an increased risk for heart disease, stroke and breast cancer, more and more women are turning to alternative and natural ways to balance their hormone levels. Studies have shown that using hormones such as Prempro, Othro-Prefest or Premphase and bioidentical HRT causes the body to shut down production of its own hormones creating a dependency. Hormone replacement therapy can also elevate existing hormone levels to toxically high amounts, which can tax the adrenal glands, burden the liver, kidneys, and circulatory and immune systems.

Yet, there is a superior way to get both clinically proven and evidence based relief without being exposed to the toxic effects of ALL of these drugs. Health providers throughout the US are using FDA registered NuFem & EndoPure Homeopathic Hormone Rejuvenation, developed by Theresa Dale, ND, CCN, NP.

In "Revitalize Your Hormones: Dr. Dale's 7 Steps to a Happier, Healthier, and Sexier You" (Wiley; May 2005; $15.95/Paper), Dr. Theresa Dale offers a medically proven alternative to invasive and dangerous hormone replacement therapies. With over 20 years of experience as a Naturopathic Doctor, Certified Clinical Nutritionist and researcher, Dr. Dale has helped women balance their hormone levels through safe, non-toxic program. The world's only clinically proven homeopathic hormone rejuvenation formulas used for restoring hormone balance without side effects. These formulas actually produce healthy hormone levels in women of various ages, and eliminate symptoms such as hot flashes, mood swings, low libido, low energy and irregular menses. The formulas are FDA approved and regulated and are prepared at an FDA registered pharmacy. The remedy goes through a lengthy preparation processes. For example, an herb or substance is diluted and prepared in a manner so that just a micro amount of the original substance is left in the final formula. This method of natural preparation enhances all the properties of the herb and amplifies its efficacy. Homeopathic medicine has been used for 200 years throughout the world, and is natural without toxic side effects. See The Wellness Center website for more education about Homeopathy.

The medical establishment's approach to balancing hormones fails to embrace the concept of the body as a natural living system that is capable of self-repair. Its regimens are based on the premise that people need to look outside our bodies for hormone help via one-size-fits-all drugs. The only hormones that are safe for the human body are the ones the body makes. By using a totally natural and homeopathic program, it is possible to restore emotional, physical and sexual health by following simple and safe individualized nutritional and exercise guidelines.

For more information, call Theresa Dale's office at 866 962 6484.

Theresa Dale, ND, CCN, NP

Founder, The Wellness Center For Research & Education, Inc.

Dean, California College of Natural Medicine

www.wellnesscenter.net

###



Contact Information Theresa Dale

The Wellness Center

http://www.wellnesscenter.net

866 962 6484

Dr. Theresa Dale, ND, CCN, NP

The Wellness Center

http://www.wellnesscenter.net

805 984 7200



Thursday, February 19, 2009

Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine

Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine

The annual Bio-IT World Conference & Expo will be held April 27-29, 2009 at the World Trade Center in Boston, MA. Since its debut in 2002, the Expo has established itself as the premier event showcasing the myriad applications of IT and informatics to biomedical research and the drug discovery enterprise. The Expo is the perfect place to share ideas and innovation through networking, education, and recognition.

Needham, MA (PRWEB) February 19, 2009 -- Networking

The Expo provides the opportunity to make connections and build alliances with peers, prospects, and thought leaders. The Expo attracts a highly influential audience consisting of senior level scientists, IT professionals and Executives from organizations across the life sciences industry including Pharmaceutical, Biotechnology, Health Systems, Academia, Government and National Laboratories. Over 1,500 delegates representing 23 countries gather to share information and discuss enabling technologies that are driving the drug discovery process.

Education

The Expo provides over 140 technology and scientific presentations. The program features six parallel tracks in the areas of: IT Infrastructure, Genomic Medicine, Predictive and in silico Science, Computational Chemistry, Clinical and Medical Informatics, and Health IT.

Keynote presentations will be featured by Chris Dagdigian, Founding Partner and Director of Technology, BioTeam, Inc.; Clifford Reid, Ph.D., Chief Executive Officer, Complete Genomics, Inc.; and Eric E. Schadt, Ph.D., Executive Scientific Director, Genetics, Rosetta Inpharmatics/Merck Research Labs.

A plenary panel discussion on the exciting field of "personal genomics" will be held. Bio-IT World magazine's Editor-in-Chief, Kevin Davies Ph.D., will moderate the discussion that will feature the most outstanding scientists, physicians and commentators in the field: Robert C. Green, M.D., M.P.H. (Boston University School of Medicine and Public Health), John Halamka, M.D., M.S. (Harvard Medical School), Clifford Reid, Ph.D. (Complete Genomics, Inc.), and Dietrich Stephan, Ph.D. (Navigenics, Inc.).

In addition to the program, pre-conference workshops, user group meetings and research poster presentations are offered.

Recognition

Attendees can view novel technologies and solutions from 75+ companies in the expansive exhibit hall. Additionally, Cambridge Healthtech Institute and Bio-IT World recognize and celebrate leaders in innovation through its "Best of Show Award", "Best Practices Award", and "Benjamin Franklin Award" Programs. The Expo is honored to provide a forum to showcase the industry's talent and imagination.

The Bio-IT World Conference & Expo is the pulse of the industry. Every year, the Event is organically produced. Contributions from the life sciences community, Bio-IT World Magazine, and trend insights help determine the themes and topics that the Event will cover from year to year. The mission of the Event always stays the same: applied learning. Through networking, education, and recognition, participants can expect to apply knowledge gained to enable technology, leverage data and transform medicine. Please visit www.bio-itworldexpo.com for more information.

About Bio-IT World

Bio-IT World (www.bio-itworld.com), the flagship publication of Cambridge Healthtech Institute (CHI), is the leading source of news on technology and strategic innovation in drug discovery, development and clinical trials. Bio-IT World's focus is increasingly one that explores the tools and results of "predictive biology" as the industry adapts to the new world of "personalized medicine." Bio-IT World has won 34 national and regional awards, more than any other magazine covering the life sciences industry. Bio-IT World, part of Cambridge Healthtech Media Group--a division of CHI--also produces a comprehensive, continually updated website, topic-specific briefings, white papers, webcasts, podcasts, conferences, and the Bio-IT World Best Practices Awards. Established in 2001, the magazine is based in Needham, Mass.

About Cambridge Healthtech Institute (CHI)

Founded in 1992, Cambridge Healthtech Institute (CHI) (www.chicorporate.com) is the industry leader offering the preeminent source of information to the leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Events, Pharmaceutical Strategy Series, Barnett International, Insight Pharma Reports, Marketing Services, and Cambridge Healthtech Media Group.

Contact: Kaushik Chaudhuri

Cambridge Healthtech Institute

(781) 972-5419

###



Contact Information Tracey Fielding

781-972-5429



Addiction Treatment Finds Success Treating Brain Deficiencies through the Belly

Addiction Treatment Finds Success Treating Brain Deficiencies through the Belly

Arche Wellness, a licensed addiction treatment program near Pittsburgh PA, has found success treating addiction by focusing on patients' malfunctioning gastrointestinal (GI) tracts. Patient data demonstrates that a consistent intake of toxins causes an addict's intestines to stop the natural absorption process. As a result of its effort to decrease toxic load, the body's GI tract inhibits absorption of many essential vitamins, minerals and amino acids, which leads to severe malnutrition, deficiencies and numerous mental health issues. The center now diagnoses and treats this condition using only vitamins, minerals and amino acids, improving the program's effectiveness and increasing treatment success.

Allison Park, PA (PRWEB) February 19, 2009 -- Today Arche Wellness announced its revolutionary four-step biochemical restoration process for treating addiction. Serving individuals throughout the state of Pennsylvania, the Department of Health licensed rehabilitation center provides a medically intensive, outpatient treatment model using only vitamins, minerals and amino acids for those struggling with addiction to alcohol, heroin, methadone, buprenorphine and prescription painkillers.

The four-step system was conceived upon the realization that almost all addicts suffer from some level of gastrointestinal (GI) problems and severe malnutrition. Patient data consistently demonstrated a correlation between GI distress and non-compliance and relapse in treatment. Through laboratory testing, the program now diagnoses the status of each patient's GI tract and repairs the body's ability to fuel itself as the first stage of treatment. Through the administration of medically supervised nutrient infusions, the center restores each patient's biochemical balance and repairs the malfunctioning GI tract to resolve the root cause of drug cravings and withdrawal symptoms. Once the GI tract is functioning properly, the body adequately fuels itself resulting in faster improvement of cognitive functioning and mental health and increased effectiveness in counseling and exercise interventions.

"Many programs look at nutritional deficits in the brain, but few if any examine the malfunctions in the mechanism that fuels the brain where the deficiency actually starts - in the gut," said Erin McClelland, MS, Executive Director of the center. "Active addicts put a lot of toxins in their bodies. These toxins cause the intestines to stop absorbing in an effort to slow contamination of the body. It is a common, natural response to a high systemic toxic load. The result is a body that is not receiving the appropriate level of amino acids, vitamins and minerals. So even when patients stop using, they remain tired, anxious and depressed."

The standard intensive, eight week program includes laboratory testing and infusions, as well as supplements, substance abuse counseling, nutritional education, physical training and spiritual enhancement. "This ensures a comprehensive, complete treatment approach and leaves no issues to chance," McClelland said. To help further this goal, the program includes twelve months of continuous aftercare free of charge, which is unprecedented in the rehabilitation field.

The use of integrative medicine and the inclusion of aftercare aren't the only features that distinguish Arche Wellness from other treatment facilities. They also utilize the Toyota Production System's philosophy of continuous improvement to achieve success. In other words, the program is an ongoing cycle of planning, implementing, refining and analyzing. As a result of this process, the center will soon be offering a specialized, less expensive service for heroin and painkiller addicts under the age of 30 because data shows these patients can recover faster with less treatment. More information on this and other Arche Wellness programs is available at www.archewellness.com.

###



Contact Information Erin McClelland

Arche Wellness

http://www.archewellness.com

724-444-1333

724-



Wednesday, February 18, 2009

A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels

A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels

Leading healthcare manufacturer introduces new product packaging and e-commerce feature to company Web site - www.geritrex.com.

Mount Vernon, NY (PRWEB) February 18, 2009 -- The Geritrex Corporation, a privately held pharmaceutical company that offers affordable, high-quality healthcare products, is now celebrating its 30th year in business. Founded by CEO and registered pharmacist Anthony Madaio, Geritrex has grown from a mid-Atlantic regional manufacturing firm to a prominent national industry leader in the over-the-counter (OTC) goods marketplace.

"Many Americans today are concerned over the fate of the pharmaceutical industry due to the looming patent expirations on branded medicinal products, however, I believe strongly that many of the smaller healthcare manufacturers - in particular the OTC producers - will hold steady during this economic downturn," said Geritrex's president Anthony Madaio. "Our company continues to remain strong and prosperous because we are continuously working very hard to develop, manufacture and market quality, value-added products while satisfying our customers' budgetary needs."

To help maintain Geritrex's competitive edge in the future, the company has recently redesigned its logo and product packaging to help refresh the brand and reinforce its market position. The company's Web site, www.geritrex.com, now features a retail element to allow consumers to make online purchases. Geritrex also plans to launch new healthcare products into the marketplace during the first quarter of 2009, including MIN-O-EAR™, an effective ear wax softener that will be priced about 50 percent less than similar products.

For 30 years, the Geritrex Corporation has been developing and producing a proprietary healthcare line, private label medical products and generic equivalents of brand name over-the-counter health items. The company's affordable, high-quality healthcare products are currently being distributed to hospitals, long-term care facilities and other institutions and there are plans to expand into the retail market this year. To learn more about the company's current offerings, please visit www.geritrex.com.

###



Contact Information Jennifer Curry-Spindola

Geritrex

http://www.geritrex.com

914-668-4003



Radiopharmaceuticals Market in US and Europe to Reach $5.4 Billion by 2015, According to New Report by Global Industry Analysts

Radiopharmaceuticals Market in US and Europe to Reach $5.4 Billion by 2015, According to New Report by Global Industry Analysts

Greater disease incidence, development of newer diagnostic agents, widespread awareness among practitioners and patients and continued breakthroughs, in research and clinical applications areas, will propel sales of radiopharmaceuticals in US and European markets to $5.4 billion by 2015.

San Jose, CA (PRWEB) February 18, 2009 -- The market for radiopharmaceuticals continues to gain momentum with heightened interest in therapeutic efficiency, acceptance and utilization of nuclear medicine equipment, as well as development of newer diagnostic and therapeutic agents. Besides oncology applications, the nuclear medicine field is presently exploring the possibility of extending the scope and functionality of radiopharmaceuticals to other disease applications such as infection imaging, nephrology and neurology applications.

Advancements in nuclear medicine technology is expected to represent a key strategic factor in opening up new clinical opportunities for radiopharmaceutical agents. Growth in Radiopharmaceuticals market (http://www.strategyr.com/Radiopharmaceuticals_Market_Report.asp) will be based on the development of new products, and robust demand for cardiology procedures, sales of oncology products, in particular, FDG for PET imaging. Establishment as well as expansion of FDG-PET reimbursement to all cancer types and also for non-oncology applications is expected to further boost the demand for radiopharmaceuticals.

The market for Diagnostic Radiopharmaceuticals (http://www.strategyr.com/Radiopharmaceuticals_Market_Report.asp) in United States is expected to grow steadily by 2012, as stated by a recent report published by Global Industry Analysts, Inc. Therapeutic Radiopharmaceuticals (http://www.strategyr.com/Radiopharmaceuticals_Market_Report.asp) market in the US will exhibit dynamic growth in response to rising efforts of companies in the development of their drug research pipeline. A surfeit of installations of PET and PET/CT diagnostic scanners is expected to boost the mature European radiopharmaceuticals market. Although regional markets offer scope for expansion, price sensitivity and unclear reimbursement policies act as a stumbling block for the European radiopharmaceuticals market.

Sales of FDG, the major PET radiopharmaceutical will continue to improve, enabling widespread use of PET scans. Increases in PET volume procedures are attributable to expanded usage of PET in oncology, novel PET radiopharmaceuticals in the research pipeline for specialized applications, efficient utilization of the NOPR and growth in cardiology applications. Closer collaborations between nuclear physicians and oncologists will help further the potential of nuclear medicine and will encourage conventional pharmaceutical companies to develop new and novel radioactive versions of available therapeutic products. Molecular imaging will increasingly be used in conjunct with therapy to determine optimum dosages, and thereby minimize side effects.

Key players dominating the US and European radiopharmaceuticals market include Actinium Pharmaceuticals Inc, Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc, Astellas Pharma US Inc, Bayer HealthCare Pharmaceuticals, Bio-Nucleonics Inc, Bracco Diagnostics Inc, Cardinal Health, Cell Therapeutics Inc, Cellectar LLC, Covidien Imaging Solutions, Cytogen Corporation, Draximage, GE Healthcare Limited, GlaxoSmithKline Plc, IBA Molecular North America Inc, Immunomedics Inc, Kimberly-Clark Inc, Lantheus Medical Imaging Inc, MDS Nordion, Molecular Insight Pharmaceuticals Inc, Peregrine Pharmaceuticals Inc, PETNET Pharmaceuticals Inc, Pharmalucence Inc, Triad Isotopes, Inc., among others.

The report titled "Radiopharmaceuticals: A US & European Market Report" published by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, key regional markets, product overview, product introductions/innovations, profiles of major players, and recent industry activity. The report analyzes market data and provides analytics in value sales for regions including the United States and Europe (France, Germany, Italy, UK, Spain, and Rest of Europe). The study also analyzes the radiopharmaceuticals market by the following product segments - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals.

For more details about this research report, please visit http://www.strategyr.com/Radiopharmaceuticals_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) (http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press (at) StrategyR (dot) com

Web Site http://www.StrategyR.com

###



Contact Information Public Relations

Global Industry Analysts, Inc.

http://www.StrategyR.com/

(408) 528-9966